Gastroparesis: A Review of Current Diagnosis and Treatment Options

Journal of Clinical Gastroenterology

Volumn 49, Issue 7, 2015, Pages 550-558

  Stein, Benjamin ^a   Everhart, Kelly K ^a   Lacy, Brian E ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

antiemetics; functional gastroduodenal disorders; gastric electrical stimulation; gastric scintigraphy; gastroparesis; nausea; prokinetics; vomiting

Indexed keywords

AMITRIPTYLINE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; APREPITANT; BOTULINUM TOXIN; CAMICINAL; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; GHRELIN; METOCLOPRAMIDE; MOTILIN RECEPTOR; NORTRIPTYLINE; OMEPRAZOLE; PHENOTHIAZINE DERIVATIVE; RELAMORELIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ABNORMAL SENSATION; ADULT; ANXIETY DISORDER; BREATH ANALYSIS; CARBON 13 BREATH TEST; CASE REPORT; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; GASTRIC PACEMAKER; GASTROSCOPY; HUMAN; HUMAN TISSUE; LIFESTYLE MODIFICATION; LOW LEVEL LASER THERAPY; MALE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MOTILITY CAPSULE; NAUSEA; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH PARESIS; STOMACH SCINTISCANNING; TREATMENT DURATION; ABDOMINAL PAIN; ABDOMINAL SURGERY; ELECTROTHERAPY; GASTROPARESIS; PHYSIOLOGY; STOMACH; STOMACH EMPTYING; UNITED STATES; VOMITING; WEIGHT REDUCTION;

ABDOMINAL PAIN; ANTIEMETICS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ELECTRIC STIMULATION THERAPY; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; NAUSEA; STOMACH; UNITED STATES; VOMITING; WEIGHT LOSS;

EID: 84937679377     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000320     Document Type: Review

References (99)

1. Camilleri M, Parkman HP, Shafi MA, et al. American College of Gastroenterology. Clinical guideline: Management of gastroparesis. Am J Gastroenterol. 2013;108:18-37, quiz 38.
2. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: Establishment of international control values. Am J Gastroenterol. 2000;95:1456-1462.
3. Guo JP, Maurer AH, Fisher RS, et al. Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci. 2001;46:24-29.
4. Ziessman HA, Bonta DV, Goetze S, et al. Experience with a simplified, standardized 4-hour gastric-emptying protocol. J Nucl Med. 2007;48:568-572.
5. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American neurogastroenterology and motility society and the society of nuclear medicine. Am J Gastroenterol. 2008;103:753-763.
6. Hoogerwerf WA, Pasricha PJ, Kalloo AN, et al. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol. 1999;94:1029-1033.
7. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398-2404.
8. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association. American gastroenterological association medical position statement: Diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1589-1591.
9. Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med. 1991;18: 229-234.
10. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264-1269.
11. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol. 1987;82:29-35.
12. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011;140:101-115.
13. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989-1996.
14. Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol. 1994;32:637-641.
15. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia. 1989;32:151-159.
16. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160:2808-2816.
17. Jung HK, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in olmsted county, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225-1233.
18. Revicki DA, Rentz AM, Dubois D, et al. Gastroparesis cardinal symptom index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004;13:833-844.
19. Ware J, Snow K, Kosinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
20. Friedenberg FK, Kowalczyk M, Parkman HP. The influence of race on symptom severity and quality of life in gastroparesis. J Clin Gastroenterol. 2013;47:757-761.
21. Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699-1706.
22. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: Efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 study group. Clin Ther. 1998; 20:438-453.
23. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92:976-980.
24. Bell RA, Jones-Vessey K, Summerson JH. Hospitalizations and outcomes for diabetic gastroparesis in North Carolina. South Med J. 2002;95:1297-1299.
25. Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005;17:35-43.
26. Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am J Gastroenterol. 2008;103:313-322.
27. Ordog T, Takayama I, Cheung WK, et al. Remodeling of networks of interstitial cells of cajal in a murine model of diabetic gastroparesis. Diabetes. 2000;49:1731-1739.
28. Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord. 2014;29:23-32.
29. Takahashi T, Nakamura K, Itoh H, et al. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology. 1997;113: 1535-1544.
30. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest. 2000;106:803.
31. Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut. 2001;49:395-401.
32. Lacy BE. Functional dyspepsia and gastroparesis: one disease or two? Am J Gastroenterol. 2012;107:1615-1620.
33. Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab. 2005;90:4489-4495.
34. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:675-680.
35. Bharucha AE, Kudva Y, Basu A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol. 2014;13:466-476.e1.
36. Sachdeva P, Malhotra N, Pathikonda M, et al. Gastric emptying of solids and liquids for evaluation for gastroparesis. Dig Dis Sci. 2011;56:1138-1146.
37. Cassilly D, Kantor S, Knight LC, et al. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil. 2008;20: 311-319.
38. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186-196.
39. Ghoos YF,Maes BD, Geypens BJ, et al.Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology. 1993;104:1640-1647
40. Lee JS, Camilleri M, Zinsmeister AR, et al. A valid, accurate, office based non-radioactive test for gastric emptying of solids. Gut. 2000;46:768-773.
41. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008;6:635.e1-643.e1.
42. Odunsi ST, Camilleri M, Szarka LA, et al. Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. Neurogastroenterol Motil. 2009;21:706.e38.
43. Olausson EA, Storsrud S, Grundin H, et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014;109:375-385.
44. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol. 1996;91:2174-2178.
45. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62: 173-181.
46. Maurer AH, Krevsky B, Knight LC, et al. Opioid and opioidlike drug effects on whole-gut transit measured by scintigraphy. J Nucl Med. 1996;37:818-822.
47. Perkel MS, Moore C, Hersh T, et al. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24:662-666.
48. Snape WJ Jr, Battle WM, Schwartz SS, et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96:444-446.
49. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463-467.
50. Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7: 25-32.
51. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11-19.
52. Merrill RM, Lyon JL, Matiaco PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013;13:152.
53. Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil. 2014;26:521-528.
54. Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379-390.
55. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94:1230-1234.
56. Straus SM, Sturkenboom MC, Bleumink GS, et al. Noncardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007-2012.
57. van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33:1003-1014.
58. Benkimoun P. French journal calls for domperidone to be withdrawn. BMJ. 2014;348:g1722.
59. Michaud V, Turgeon J. Domperidone and sudden cardiac death: How much longer should we wait? J Cardiovasc Pharmacol. 2013;61:215-217.
60. Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102:823-828.
61. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322:1028-1031.
62. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98:259-263.
63. Quigley EM. Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis. 2011;12:147-156.
64. Yamamoto T, Tajimi M, Takahashi N, et al. First-in-human study of the novel 5-HT4 agonist, RQ-00000010, demonstrated acceleration of gastric emptying following single and multiple oral administration to healthy human subjects. Gastroenterology. 2013;144:S-736.
65. Simmons K, Parkman HP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci. 2014;59:1231-1234.
66. Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother. 2012;46:e38.
67. Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol. 2009;5:285-288.
68. McCallum R, Sunny J. Status of pharmacological management of gastroparesis: 2014. Practical Gastroenterol. 2014;38: 20-42.
69. Prakash C, Lustman PJ, Freedland KE, et al. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci. 1998;43:1951-1956.
70. Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007;52:418-424.
71. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310:2640-2649.
72. Ejskjaer N, Vestergaard ET, Hellstrom PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179-1187.
73. Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010;22:1069-e281.
74. Wo JM, Ejskjaer N, Hellstrom PM, et al. Randomised clinical trial: Ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting-randomised clinical study subset data. Aliment Pharmacol Ther. 2011;33:679-688.
75. Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25:e140-e150.
76. McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25:e705-e717.
77. Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013;11:1453.e4-1459.e4.
78. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013;36:41-48.
79. Lembo A, Camilleri M, McCallum R, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology. 2014;46:S-158-S-159.
80. Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Expert Opin Investig Drugs. 2015;24:133-140.
81. Barton M, Otiker T, Johnson L, et al. A randomized, doubleblind, placebo-controlled phase II study (MOT114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis. Gastroenterology. 2014;146:S-20.
82. Lacy BE, Crowell MD, Schettler-Duncan A, et al. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27:2341-2347.
83. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: A randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251-1258.
84. Friedenberg FK, Palit A, Parkman HP, et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416-423.
85. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125:421-428.
86. McCallum RW, Sarosiek I, Parkman HP, et al. Gastric electrical stimulation with enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterol Motil. 2013;25: 815-e636.
87. McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8:947-954, quiz e116.
88. Chu H, Lin Z, Zhong L, et al. Treatment of high-frequency gastric electrical stimulation for gastroparesis. J Gastroenterol Hepatol. 2012;27:1017-1026.
89. O'Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009;33:1693-1701.
90. Keller DS, Parkman HP, Boucek DO, et al. Surgical outcomes after gastric electric stimulator placement for refractory gastroparesis. J Gastrointest Surg. 2013;17:620-626.
91. Sarosiek I, Forster J, Lin Z, et al. The addition of pyloroplasty as a new surgical approach to enhance effectiveness of gastric electrical stimulation therapy in patients with gastroparesis. Neurogastroenterol Motil. 2013;25:134-e80.
92. Lacy BE, Weiser K. Gastric motility, gastroparesis, and gastric stimulation. Surg Clin North Am. 2005;85:967-987, vi-vii.
93. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc. 1998;47:67-70.
94. Maple JT, Petersen BT, Baron TH, et al. Direct percutaneous endoscopic jejunostomy: outcomes in 307 consecutive attempts. Am J Gastroenterol. 2005;100:2681-2688.
95. Toro JP, Lytle NW, Patel AD, et al. Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis. J Am Coll Surg. 2014;218:652-660.
96. Borrazzo EC. Surgical management of gastroparesis: gastrostomy/jejunostomy tubes, gastrectomy, pyloroplasty, gastric electrical stimulation. J Gastrointest Surg. 2013;17:1559-1561.
97. Forstner-Barthell AW, Murr MM, Nitecki S, et al. Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients. J Gastrointest Surg. 1999;3:15-21, discussion 21-23.
98. Zehetner J, Ravari F, Ayazi S, et al. Minimally invasive surgical approach for the treatment of gastroparesis. Surg Endosc. 2013;27:61-66.
99. Papasavas PK, Ng JS, Stone AM, et al. Gastric bypass surgery as treatment of recalcitrant gastroparesis. Surg Obes Relat Dis. 2014;10:795-799.